Cor brokering three-way deal for partner; Ciba/Medarex example of pharma reducing risk -- GBR conference.
COR BROKERING THREE-WAY DEAL FOR UNNAMED PARTNER, Cor Therapeutics Director of Business Development Jane Lange told a Global Business Research licensing conference in Washington, D.C. July 27. Cor is negotiating the non-traditional deal between one of its four pharmaceutical partners and another biotechnology firm to gain access to the biotech's technology for both Cor and its partner, Lange said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth